Daiichi Sankyo

Candidate Targets Indication Partner Our Commercial
Rights
Discovery Preclinical IND-
enabling
Phase I Phase Ib/IIa
Daiichi Sankyo n.d. n.d. Milestones & Royalties
Discovery Phase completed
Pre-Clinical Phase completed
IND-enabling Phase in progress
Phase 1 not started
Phase 2 not started

On April 12, 2011, Pieris announced the initiation of a therapeutic discovery and development partnership with Daiichi Sankyo. To date the company has achieved nine milestones in this collaboration and Daiichi Sankyo is currently developing an Anticalin protein against an undisclosed target, which in the IND-enabling activities stage.